Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc. is positioned favorably within the oncology market due to its development of innovative therapies targeting ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), with potential peak revenues projected to exceed $3.6 billion. The effectiveness of its candidates, such as NVL-520 and NVL-655, is underscored by their ability to deliver durable antitumor responses and improved tolerability, which may significantly reshape treatment approaches and broaden market penetration. Additionally, the company's strategic initiatives, such as the incorporation of RNA-based NGS for ROS1 detection and favorable data from ongoing studies, enhance the likelihood of expanded sales opportunities in a competitive landscape dominated by established therapies like Alecensa and Xalkori.

Bears say

Nuvalent Inc faces a negative outlook primarily due to concerns regarding its clinical trial results and safety profiles, which may hinder regulatory approval and competitive positioning. The potential for adverse regulatory decisions, coupled with the risks of disappointing efficacy and unforeseen delays in research and development, poses significant threats to the company's commercialization timeline. Additionally, the company's challenges in raising sufficient capital for ongoing research efforts further contribute to the adverse financial outlook by limiting its ability to sustain operations and innovate.

Nuvalent (NUVL) has been analyzed by 15 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 15 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $135, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $135, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.